RYTM Share Price Performance
US$93.00
44.44 (91.52%)
29.3% undervalued intrinsic discount
US$131.50
Fair Value
Price US$93.00
Vestra US$131.50
AnalystConsensusTarget US$139.67
Fair ValueUS$131.50
Share Pricen/a
Rhythm Pharmaceuticals, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
RYTM Community Narratives
VE
Fair Value US$131.5 29.3% undervalued intrinsic discount
Rhythm Pharmaceuticals (RYTM): The Rare Obesity Monopoly – Countdown to the March 20th PDUFA Catalyst.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$139.67 33.4% undervalued intrinsic discount
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Rhythm Pharmaceuticals (RYTM): The Rare Obesity Monopoly – Countdown to the March 20th PDUFA Catalyst.
Rhythm Pharmaceuticals is currently operating at the center of the "rare neuroendocrine" revolution, successfully carving out a niche that remains largely untouched by the broader GLP-1 price wars. Trading at $93.52 as of the March 6, 2026 close, the stock has shown significant strength, rising 2.25% on the final trading day of the week.Read more
37
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
Key Takeaways Expansion into new indications and age groups, alongside global diagnostic trends, positions Rhythm for sustained patient base and revenue growth. Strong intellectual property and regulatory advantages ensure high margins, pricing power, and long-term resilience against competitive threats.Read more
123
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$139.67
33.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Profit Margin
28.18%
Future PE
54.47x
Price in 2029
US$170.25
Trending Discussion
Recently Updated Narratives
VE
Rhythm Pharmaceuticals (RYTM): The Rare Obesity Monopoly – Countdown to the March 20th PDUFA Catalyst.
Fair Value: US$131.5 29.3% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase
Fair Value: US$139.67 33.4% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Rhythm Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -2.96
- 89.73%
- -106.41%
- 40.1%
About RYTM
- Founded
- 2008
- Employees
- 414
- CEO
- WebsiteView website
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
